X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (186) 186
Publication (27) 27
Book Chapter (9) 9
Patent (7) 7
Book / eBook (4) 4
Conference Proceeding (3) 3
Paper (3) 3
Book Review (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (45) 45
female (42) 42
index medicus (40) 40
middle aged (31) 31
oncology (31) 31
aged (30) 30
adult (26) 26
ovarian cancer (20) 20
cancer (19) 19
physics - solar and stellar astrophysics (19) 19
chemotherapy (18) 18
physics - astrophysics of galaxies (18) 18
physics - cosmology and nongalactic astrophysics (18) 18
physics - earth and planetary astrophysics (18) 18
physics - high energy astrophysical phenomena (18) 18
physics - instrumentation and methods for astrophysics (18) 18
aged, 80 and over (16) 16
analysis (14) 14
mutation (13) 13
tumors (13) 13
ovarian neoplasms - drug therapy (11) 11
carcinoma (10) 10
clinical trials (10) 10
life sciences (10) 10
ovarian neoplasms - pathology (10) 10
antineoplastic agents - therapeutic use (9) 9
chemistry (9) 9
male (9) 9
management (9) 9
prognosis (9) 9
neoplasm staging (8) 8
antineoplastic agents - adverse effects (7) 7
astrophysics (7) 7
bevacizumab (7) 7
breast cancer (7) 7
care and treatment (7) 7
disease-free survival (7) 7
human necessities (7) 7
hygiene (7) 7
medical or veterinary science (7) 7
metallurgy (7) 7
organic chemistry (7) 7
ovarian neoplasms - mortality (7) 7
pathology (7) 7
peptides (7) 7
preparations for medical, dental, or toilet purposes (7) 7
research (7) 7
surgery (7) 7
survival (7) 7
young adult (7) 7
[ phys.astr.co ] physics [physics]/astrophysics [astro-ph]/cosmology and extra-galactic astrophysics [astro-ph.co] (6) 6
[phys.astr.co]physics [physics]/astrophysics [astro-ph]/cosmology and extra-galactic astrophysics [astro-ph.co] (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
benin (6) 6
follow-up studies (6) 6
neoplasm recurrence, local (6) 6
ovarian neoplasms - genetics (6) 6
prospective studies (6) 6
structure (6) 6
studies (6) 6
survival rate (6) 6
trial (6) 6
uterine neoplasms - pathology (6) 6
uterus (6) 6
[sdv]life sciences [q-bio] (5) 5
chemistry, multidisciplinary (5) 5
deoxyribonucleic acid--dna (5) 5
double-blind method (5) 5
drug therapy (5) 5
earth and planetary astrophysics (5) 5
farmers (5) 5
galaxy astrophysics (5) 5
genetic aspects (5) 5
gynecology (5) 5
hematology, oncology and palliative medicine (5) 5
immunohistochemistry (5) 5
leiomyosarcoma (5) 5
obstetrics & gynecology (5) 5
ovarian carcinoma (5) 5
ovarian neoplasms - surgery (5) 5
paclitaxel (5) 5
patients (5) 5
risk (5) 5
risk assessment (5) 5
solar and stellar astrophysics (5) 5
therapy (5) 5
tungsten (5) 5
[ sdu.astr ] sciences of the universe [physics]/astrophysics [astro-ph] (4) 4
[sdu.astr]sciences of the universe [physics]/astrophysics [astro-ph] (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
astronomy & astrophysics (4) 4
biomarkers (4) 4
brca1 protein (4) 4
business administration (4) 4
cancer research (4) 4
carboplatin - administration & dosage (4) 4
carcinoma, ovarian epithelial (4) 4
cosmology and extragalactic astrophysics (4) 4
doxorubicin (4) 4
endometrial neoplasms - pathology (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Cancer, ISSN 0020-7136, 04/2019, Volume 144, Issue 8, pp. 1962 - 1974
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
by Coleman, Robert L and Coleman, R L and Oza, Amit M and Oza, A M and Lorusso, D and Lorusso, Domenica and Aghajanian, C and Aghajanian, Carol and Oaknin, A and Oaknin, Ana and Dean, A and Dean, Andrew and Colombo, N and Colombo, Nicoletta and Weberpals, Johanne I and Weberpals, J I and Clamp, Andrew and Clamp, A and Scambia, Giovanni and Scambia, G and Leary, A and Leary, Alexandra and Holloway, Robert W and Holloway, R W and Gancedo, M Amenedo and Gancedo, Margarita Amenedo and Fong, Peter C and Fong, P C and Goh, Jeffrey C and Goh, J C and O'Malley, David M and O'Malley, D M and Armstrong, Deborah K and Armstrong, D K and Garcia-Donas, Jesus and Garcia-Donas, J and Swisher, E M and Swisher, Elizabeth M and Floquet, A and Floquet, Anne and Konecny, Gottfried E and Konecny, G E and McNeish, I A and McNeish, Iain A and Scott, C L and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, J A and Ledermann, Jonathan A and Buck, M and Friedlander, M L and Harnett, P and Kichenadasse, G and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Plante, M and Provencher, D and Welch, S and Gladieff, L and Joly, F and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Pignata, S and Sabbatini, R F and Tamberi, S and Zamagni, C and O'Donnell, A and Herraez, A Casado and Guerra, E M and Palacio, I and Romero, I and Sanchez, A and ... and ARIEL3 Investigators and ARIEL3 investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | ADP | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2018, Volume 13, Issue 10, p. e0204973
Journal Article
European Journal of Cancer, ISSN 0959-8049, 07/2019, Volume 116, pp. 35 - 44
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 457 - 464
Journal Article
1999, Working papers on African societies. Documents de travail sur les sociétés africaines = Arbeitspapiere zu afrikanischen Gesellschaften, Volume Nr. 33., 51
Book
by Pujade-Lauraine, Eric and Ledermann, Jonathan and Ledermann, Jonathan A and Selle, Frédéric and Gebski, Val and Penson, Richard and Penson, Richard T and Oza, Amit M and Oza, Amit and Korach, Jacob and Huzarski, Tomasz and Poveda, Andrés and Pignata, Sandro and Friedlander, Michael and Colombo, Nicoletta and Harter, Philipp and Fujiwara, Keiichi and Ray-Coquard, Isabelle and Banerjee, Susana and Liu, Joyce and Lowe, Elizabeth S and Bloomfield, Ralph and Pautier, Patricia and Byrski, Tomasz and Scambia, Giovanni and Nicoletto, Maria and Nussey, Fiona and Clamp, Andrew and Poveda Velasco, Andrés and Rodrigues, Manuel and Lotz, Jean-Pierre and Provencher, Diane and Prat Aparicio, Aleix and Vidal Boixader, Laura and Scott, Clare and Tamura, Kenji and Yunokawa, Mayu and Lisyanskaya, Alla and Medioni, Jacques and Pécuchet, Nicolas and Dubot, Coraline and de la Motte Rouge, Thibault and Kaminsky, Marie-Christine and Weber, Béatrice and Lortholary, Alain and Parkinson, Christine and Williams, Sarah and Cosin, Jonathan and Hoffman, James and Plante, Marie and Covens, Allan and Sonke, Gabe and Joly, Florence and Floquet, Anne and Hirte, Holger and Amit, Amnon and Park-Simon, Tjoung-Won and Matsumoto, Koji and Tjulandin, Sergei and Kim, Jae Hoon and Kim, Byoung-Gie and Kim, Jae Weon and Gladieff, Laurence and Sabbatini, Roberto and O'Malley, David and Timmins, Patrick and Kredentser, Daniel and Laínez Milagro, Nuria and Barretina Ginesta, Maria Pilar and Tibau Martorell, Ariadna and Gómez de Liaño Lista, Alfonso and Ojeda González, Belén and Mileshkin, Linda and Mandai, Masaki and Boere, Ingrid and Ottevanger, Petronella and Nam, Joo-Hyun and Filho, Elias and Hamizi, Salima and Cognetti, Francesco and Warshal, David and Dickson-Michelson, Elizabeth and Kamelle, Scott and McKenzie, Nathalie and Rodriguez, Gustavo and Armstrong, Deborah and Chalas, Eva and Celano, Paul and Behbakht, Kian and Davidson, Susan and Welch, Stephen and Helpman, Limor and Fishman, Ami and Bruchim, Ilan and Sikorska, Magdalena and Słowińska, Anna and Rogowski, Wojciech and Bidziński, Mariusz and Śpiewankiewicz, Beata and Casado Herraez, Antonio and ... and SOLO2-ENGOT-Ov21 Investigators and SOLO2/ENGOT-Ov21 investigators
The Lancet Oncology, ISSN 1470-2045, 09/2017, Volume 18, Issue 9, pp. 1274 - 1284
Journal Article
Journal Article